Opsona Therapeutics appoints chief medical officer
Chief executive steps down for personal reasons
Chief executive Dr Mark Heffernan has stepped down for personal reasons but will remain as a non-executive board member. Bernd Seizinger has been appointed executive chairman and will oversee the search for a new ceo and assume additional responsibilities for the company's operations during this period.
To further strengthen the executive management team, one of the company's founding scientists and directors, Professor Luke O'Neill will assume the additional role of chief scientific officer.
Opsona's vp of pharmaceutical development, Mary Reilly, has taken a broader role within the company as vice president of pharmaceutical development and operations.
You may also like
Research & Development
Dual inhibition of motor proteins KIF18A and CENP-E shown to selectively kill cancer cells
Researchers from Osaka University and MIT have discovered that blocking two cooperative motor proteins involved in chromosome alignment can trigger cancer cell death, revealing a promising new target for anticancer therapies
Research & Development
Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development
Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies